Mesothelioma Therapy Immunotherapy and Targeted Therapy

Question 1

Which immunotherapy regimen received FDA approval for first-line treatment of unresectable pleural mesothelioma?

Accepted Answer

Nivolumab + ipilimumab

Answer

Pembrolizumab monotherapy

Answer

Atezolizumab + bevacizumab

Answer

Durvalumab + tremelimumab

Question 2

Nivolumab is classified as which type of immunotherapy?

Accepted Answer

PD-1 checkpoint inhibitor

Answer

CTLA-4 inhibitor

Answer

CAR-T cell therapy

Answer

Cancer vaccine

Question 3

Ipilimumab targets which immune checkpoint?

Accepted Answer

CTLA-4

Answer

PD-1

Answer

PD-L1

Answer

LAG-3

Question 4

In the CheckMate 743 trial, nivolumab + ipilimumab showed the greatest benefit in which mesothelioma subgroup?

Accepted Answer

Non-epithelioid (sarcomatoid/biphasic) cell type

Answer

Epithelioid cell type

Answer

Stage I patients

Answer

Patients with prior surgery

Question 5

What is a common immune-related adverse event (irAE) associated with checkpoint inhibitors in mesothelioma?

Accepted Answer

Colitis, pneumonitis, hepatitis, and endocrinopathies

Answer

Nephrotoxicity and neuropathy

Answer

Myelosuppression only

Answer

Alopecia and nail changes

Question 6

High-dose corticosteroids are used to treat severe immune-related adverse events (irAEs) from checkpoint inhibitors. Why?

Accepted Answer

To suppress the overactive immune response causing organ damage

Answer

To enhance anti-tumor immunity

Answer

To improve drug absorption

Answer

To prevent infection only